
ROIV
Roivant Sciences Ltd
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
11.645
Open
11.580
VWAP
11.50
Vol
4.36M
Mkt Cap
7.85B
Low
11.350
Amount
50.13M
EV/EBITDA(TTM)
--
Total Shares
738.72M
EV
3.46B
EV/OCF(TTM)
--
P/S(TTM)
292.94
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
7.16M
-87.02%
--
--
7.26M
-75.2%
--
--
7.52M
-16.66%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Roivant Sciences Ltd. (ROIV) for FY2026, with the revenue forecasts being adjusted by 17.19% over the past three months. During the same period, the stock price has changed by 3.22%.
Revenue Estimates for FY2026
Revise Upward

+17.19%
In Past 3 Month
Stock Price
Go Up

+3.22%
In Past 3 Month
7 Analyst Rating

29.87% Upside
Wall Street analysts forecast ROIV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ROIV is 15.00 USD with a low forecast of 12.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy

29.87% Upside
Current: 11.550

Low
12.00
Averages
15.00
High
18.00

29.87% Upside
Current: 11.550

Low
12.00
Averages
15.00
High
18.00
JPMorgan
Brian Cheng
Overweight
maintain
$16
2025-07-25
New
Reason
JPMorgan
Brian Cheng
Price Target
$16
2025-07-25
New
maintain
Overweight
Reason
JPMorgan analyst Brian Cheng placed Roivant Sciences on "Positive Catalyst Watch" while keeping an Overweight rating on the shares with a $16 price target. The firm expects brepocitinib's pivotal readout in dermatomyositis to occur in the early part of the back half of the year. It believes brepocitinib's mechanism of action is already de-risked based on published case studies. JPMogan thinks the drug will become the preferred JAKi in a major portion of the dermatomyositis market.
Goldman Sachs
NULL -> Buy
initiated
$19
2025-07-10
Reason
Goldman Sachs
Price Target
$19
2025-07-10
initiated
NULL -> Buy
Reason
Goldman Sachs resumed coverage of Roivant Sciences with a Buy rating and $19 price target. The firm is positive on a successful clinical outcome for the Phase 3 VALOR data.
JPMorgan
Overweight
maintain
2025-06-19
Reason
JPMorgan
Price Target
2025-06-19
maintain
Overweight
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$18
2025-04-21
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$18
2025-04-21
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$18
2025-02-11
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$18
2025-02-11
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$18
2024-11-13
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$18
2024-11-13
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Roivant Sciences Ltd (ROIV.O) is -8.99, compared to its 5-year average forward P/E of -7.11. For a more detailed relative valuation and DCF analysis to assess Roivant Sciences Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-7.11
Current PE
-8.99
Overvalued PE
-2.53
Undervalued PE
-11.68
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-3.05
Current EV/EBITDA
-2.52
Overvalued EV/EBITDA
-0.61
Undervalued EV/EBITDA
-5.50
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Overvalued
5Y Average PS
64.77
Current PS
262.98
Overvalued PS
122.80
Undervalued PS
6.73
Financials
Annual
Quarterly
FY2025Q4
YoY :
-16.08%
7.57M
Total Revenue
FY2025Q4
YoY :
+37.77%
-284.97M
Operating Profit
FY2025Q4
YoY :
+165.78%
-252.38M
Net Income after Tax
FY2025Q4
YoY :
+52.63%
-0.29
EPS - Diluted
FY2025Q4
YoY :
+59.34%
-173.38M
Free Cash Flow
FY2025Q4
YoY :
+14.80%
97.29
Gross Profit Margin - %
FY2025Q4
YoY :
+372.91%
-2.91K
FCF Margin - %
FY2025Q4
YoY :
+428.50%
-3.33K
Net Margin - %
FY2025Q4
YoY :
-100.00%
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
46.2M
USD
11
3-6
Months
17.2M
USD
7
6-9
Months
23.2M
USD
9
0-12
Months
96.2M
USD
12
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
336.9M
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
6.6M
Volume
5
6-9
Months
13.4M
Volume
5
0-12
Months
239.0K
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
2
1.4M
Volume
Months
6-9
6
6.5M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
46.2M
USD
11
3-6
Months
17.2M
USD
7
6-9
Months
23.2M
USD
9
0-12
Months
96.2M
USD
12
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
336.9M
USD
Months
0-12
0
0.0
USD
Months
ROIV News & Events
Events Timeline
2025-06-25 (ET)
2025-06-25
07:45:44
Roivant Sciences announces $500M share repurchase program

2025-06-16 (ET)
2025-06-16
07:07:18
Pulmovant announces publication of PK, lung deposition data for mosliciguat

2025-05-29 (ET)
2025-05-29
07:05:12
Roivant Sciences reports Q4 EPS (29c), consensus (16c)

Sign Up For More Events
Sign Up For More Events
News
8.0
06-25SeekingAlphaRoivant Sciences sets $500M stock repurchase program
5.0
06-23NASDAQ.COMInsider Sale: 10% owner at $ROIV Sells 565,266 Shares
9.0
06-16NewsfilterPulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics
Sign Up For More News
People Also Watch

BBWI
Bath & Body Works Inc
31.560
USD
+0.41%

LSCC
Lattice Semiconductor Corp
53.790
USD
+2.95%

HAS
Hasbro Inc
74.980
USD
-0.09%

QRVO
Qorvo Inc
85.280
USD
-1.06%

X
United States Steel Corp
0
USD
-0.02%

CX
Cemex SAB de CV
8.410
USD
+1.94%

WING
Wingstop Inc
302.010
USD
+0.79%

LPX
Louisiana-Pacific Corp
89.840
USD
+1.54%

WH
Wyndham Hotels & Resorts Inc
92.000
USD
+3.58%

MKSI
MKS Inc
99.500
USD
-0.04%
FAQ

What is Roivant Sciences Ltd (ROIV) stock price today?
The current price of ROIV is 11.55 USD — it has increased 1.49 % in the last trading day.

What is Roivant Sciences Ltd (ROIV)'s business?

What is the price predicton of ROIV Stock?

What is Roivant Sciences Ltd (ROIV)'s revenue for the last quarter?

What is Roivant Sciences Ltd (ROIV)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Roivant Sciences Ltd (ROIV)'s fundamentals?

How many employees does Roivant Sciences Ltd (ROIV). have?
